Quarterly report pursuant to Section 13 or 15(d)

Stockholders??? Equity (Details Narrative)

v3.21.2
Stockholders’ Equity (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 03, 2021
Jun. 19, 2021
Jun. 19, 2021
Jun. 19, 2020
Jan. 14, 2020
Jun. 19, 2018
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Dec. 31, 2020
Class of Stock [Line Items]                      
Research and Development Expense             $ 4,621,255 $ 3,336,225 $ 10,343,451 $ 10,833,345  
Proceeds from Issuance Initial Public Offering         $ 50,000,000.0       $ 5,580,471 $ 46,639,210  
Preferred stock, shares outstanding             0   0   4,361
Dividend description                 (i) a number of shares of common stock equal to 10% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2019, (ii) a number of shares of common stock equal to 15% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2020 and (iii) a number of shares of common stock equal to 20% of the shares of common stock underlying the Series B Preferred Stock then held by such holder on June 19, 2021.    
Number of warrant to purchase of common stock             988,000   988,000    
Minimum [Member]                      
Class of Stock [Line Items]                      
Conversion price per share             $ 0.50   $ 0.50    
Maximum [Member]                      
Class of Stock [Line Items]                      
Conversion price per share             0.75   0.75    
Merger Warrants [Member]                      
Class of Stock [Line Items]                      
Proceeds from Issuance Initial Public Offering         $ 46,600,000            
BTIGLLC [Member]                      
Class of Stock [Line Items]                      
Average price per shares             $ 1.90   $ 1.90    
Gross proceeds from common stock                 $ 5,800,000    
Common Stock [Member]                      
Class of Stock [Line Items]                      
Share Price         $ 1.55            
Number of underwritten public offering of common stock   8,436,000     32,300,000       3,023,147 32,260,000  
Number share issued upon conversion                 8,722,000 50,000  
Series B Preferred Stock [Member]                      
Class of Stock [Line Items]                      
Number share issued upon conversion           8,000          
Preferred stock converted   2,000 2,000                
Preferred stock, shares outstanding             0   0   4,361
Series B Preferred Stock [Member] | Common Stock [Member]                      
Class of Stock [Line Items]                      
Dividend shares     1,687,200 1,365,600              
Aquarius Merger Agreement [Member] | Holders Of Aquarius Biotechnologies Inc [Member] | Unregistered Shares [Member]                      
Class of Stock [Line Items]                      
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares 1,500,000                    
Research and Development Expense $ 1,200,000                    
Share Price $ 0.80                    
Sales Agreement [Member] | Underwritten Public Offering [Member]                      
Class of Stock [Line Items]                      
Gross proceeds from common stock                 $ 5,600,000